Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA funding

This article was originally published in The Tan Sheet

Executive Summary

House passes agriculture spending bill by 414-16 vote July 11; Senate Appropriations Committee will take up legislation July 17. Bill includes $4.14 bil. for Special Supplemental Nutrition Program for Women, Infants & Children (WIC) and an amendment to provide an additional $2.5 mil. for FDA's Office of Generic Drugs. Agency and center funding remains largely unchanged since June debate (1"The Tan Sheet" June 18, In Brief)

You may also be interested in...



Mead Enfamil Sales Buoy Bristol-Myers Nutritionals In Q2

Increased spending on consumer ads and promos for Enfamil infant formula helped the brand post worldwide sales gains of roughly 8% to $172 mil. for the second quarter, Bristol-Myers Squibb's Mead Johnson division said July 25.

Mead Enfamil Sales Buoy Bristol-Myers Nutritionals In Q2

Increased spending on consumer ads and promos for Enfamil infant formula helped the brand post worldwide sales gains of roughly 8% to $172 mil. for the second quarter, Bristol-Myers Squibb's Mead Johnson division said July 25.

Mead Enfamil Sales Buoy Bristol-Myers Nutritionals In Q2

Increased spending on consumer ads and promos for Enfamil infant formula helped the brand post worldwide sales gains of roughly 8% to $172 mil. for the second quarter, Bristol-Myers Squibb's Mead Johnson division said July 25.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel